NCT02736305

Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

Completed Phase 2 Last updated 13 June 2022

What this trial tests

Phase 2 trial testing Regorafenib in Ovarian Neoplasms in 21 participants. Completed in 18 November 2019.

Timeline

3 February 2016

Primary endpoint
18 November 2019

18 November 2019

Quick facts

Lead sponsor	National Cancer Centre, Singapore
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	3 February 2016
Primary completion	18 November 2019
Estimated completion	18 November 2019
Sites	1 location across Singapore

Drugs / interventions tested

• Regorafenib — full drug profile →

Conditions studied

• Ovarian Neoplasms — all drugs for Ovarian Neoplasms →

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 99, female only, with Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1 Proto-Oncogene, Serine/Threonine Kinase (RAF1) and BRAF) and tumour growth (PDGFR and FGFR). Epithelial ovarian cancer (EOC) cell lines frequently express high levels of vascular endothelial growth factor (VEGF) and in vivo preclinical studies evaluating Regorafenib have shown promising activity in ovarian cancer. In the clinic, anti-angiogenesis therapy with bevacizumab (a monoclonal antibody to VEGF) has already emerged as an important cornerstone in the management of ovarian cancer both as part of frontline adjuvant treatment and as second-line therapy for platinum-sensitive recurrent disease. Whilst Regorafenib has been FDA approved for the treatment of patients with metastatic colorectal cancer who have failed prior bevacizumab, it's role in the management of ovarian cancer remains to be defined.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
   Yang Y, Yang Y, Yang J, Zhao X, et al · · 2020 · cited 168× · PMID 32850861 · DOI 10.3389/fcell.2020.00758
2. FGFR3-TACC3 fusion in solid tumors: mini review.
   Costa R, Carneiro BA, Taxter T, Tavora FA, et al · · 2016 · cited 107× · PMID 27409839 · DOI 10.18632/oncotarget.10482
3. Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy.
   Jin C, Yuan M, Bu H, Jin C. · · 2022 · cited 36× · PMID 35466318 · DOI 10.1155/2022/4880355
4. Inferring cancer disease response from radiology reports using large language models with data augmentation and prompting.
   Tan RSYC, Lin Q, Low GH, Lin R, et al · · 2023 · cited 27× · PMID 37451682 · DOI 10.1093/jamia/ocad133
5. Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements.
   Wang Y, Zhu N, Liu J, Chen F, et al · · 2025 · cited 15× · PMID 40369674 · DOI 10.1186/s12967-025-06508-0
6. Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers.
   Zhu DL, Tuo XM, Rong Y, Zhang K, et al · · 2020 · cited 15× · PMID 33193890 · DOI 10.7150/jca.44727
7. How to win the ovarian cancer stem cell battle: destroying the roots.
   Takahashi A, Hong L, Chefetz I. · · 2020 · cited 13× · PMID 35582216 · DOI 10.20517/cdr.2020.93
8. Somatic Variant Analysis Identifies Targets for Tailored Therapies in Patients with Vascular Malformations.
   Paolacci S, Mattassi RE, Marceddu G, Manara E, et al · · 2020 · cited 8× · PMID 33105631 · DOI 10.3390/jcm9113387